Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more
Market Cap & Net Worth: Supriya Lifescience Limited (SUPRIYA)
Supriya Lifescience Limited (NSE:SUPRIYA) has a market capitalization of $533.90 Million (₹46.24 Billion) as of March 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #15876 globally and #705 in its home market, demonstrating a -7.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Supriya Lifescience Limited's stock price ₹574.50 by its total outstanding shares 80482800 (80.48 Million).
Supriya Lifescience Limited Market Cap History: 2021 to 2026
Supriya Lifescience Limited's market capitalization history from 2021 to 2026. Data shows growth from $447.24 Million to $533.90 Million (9.69% CAGR).
Index Memberships
Supriya Lifescience Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$68.11 Billion | 0.25% | #117 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.01% | #543 of 750 |
Weight: Supriya Lifescience Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Supriya Lifescience Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Supriya Lifescience Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
Supriya Lifescience Limited's market cap is 0.10 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.37x
Supriya Lifescience Limited's market cap is 0.37 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $447.24 Million | $3.85 Billion | $1.24 Billion | 0.12x | 0.36x |
| 2022 | $217.70 Million | $5.19 Billion | $1.52 Billion | 0.04x | 0.14x |
| 2023 | $292.12 Million | $4.51 Billion | $898.57 Million | 0.06x | 0.33x |
| 2024 | $687.51 Million | $5.70 Billion | $1.19 Billion | 0.12x | 0.58x |
| 2025 | $698.39 Million | $6.96 Billion | $1.88 Billion | 0.10x | 0.37x |
Competitor Companies of SUPRIYA by Market Capitalization
Companies near Supriya Lifescience Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Supriya Lifescience Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Supriya Lifescience Limited Historical Marketcap From 2021 to 2026
Between 2021 and today, Supriya Lifescience Limited's market cap moved from $447.24 Million to $ 533.90 Million, with a yearly change of 9.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹533.90 Million | -23.55% |
| 2025 | ₹698.39 Million | +1.58% |
| 2024 | ₹687.51 Million | +135.35% |
| 2023 | ₹292.12 Million | +34.18% |
| 2022 | ₹217.70 Million | -51.32% |
| 2021 | ₹447.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Supriya Lifescience Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $533.90 Million USD |
| MoneyControl | $533.90 Million USD |
| MarketWatch | $533.90 Million USD |
| marketcap.company | $533.90 Million USD |
| Reuters | $533.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.